Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

Submitted by admin on June 14, 2023 - 10:08am
Source: 
BioSpace
News Tags: 
Merck
efinopegdutide
FDA
NASH
fast track
Headline: 
Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide
snippet: 

Monday, Merck announced that its GLP-1/glucagon receptor co-agonist efinopegdutide had won the FDA’s Fast Track designation for treating non-alcoholic steatohepatitis.

Do Not Allow Advertisers to Use My Personal information